OS Therapies Incorporated (OSTX)

OS Therapies reported Q3 2025 earnings miss, which led to a stock price decline. The company announced positive Phase 2b biomarker data for OST-HER2. OS Therapies initiated a BLA submission for OST-HER2 and had productive regulatory meetings. The company raised $7.53 million through warrant exercise inducement agreements. OS Therapies applauded the reauthorization of the Rare Pediatric Disease Priority Review Voucher Program. The company plans to spin off its OS Animal Health subsidiary.

Demand for OS Therapies' products is not subject to traditional seasonality. Demand is primarily driven by disease incidence, unmet medical need, clinical trial success and regulatory approvals, and physician and patient adoption.

OS Therapies, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for osteosarcoma and other solid tumors. Their pipeline includes OST-HER2, an off-the-shelf immunotherapy, and OST-tADC, a tunable Antibody-Drug Conjugate platform. The company was incorporated in 2018 and went public on August 1, 2024.

OS Therapies, Inc. is a US-based company with clinical trials for OST-HER2 conducted across 21 sites in the United States. The company is pursuing regulatory approvals and planning for potential commercialization in the United States, the United Kingdom, and Europe.

OS Therapies, Inc. has maintained a generally positive brand reputation. A documentary featuring OS Therapies' OST-HER2 immunotherapy received two 2025 Daytime Emmy nominations. Analysts have a "Moderate Buy" consensus rating for OSTX. Challenges include the complexities of osteosarcoma, its poor responsiveness to certain therapies, and the historical track record of Listeria-based immunotherapies.

OS Therapies, Inc. has 32 institutional owners and shareholders holding a total of 1,990,506 shares. Individual and insider ownership accounts for 15.71% of shares outstanding, while institutional ownership is 5.45%. Paul Romness, the Chairman and CEO, holds 7.023% of the equities.